|
|
|
|
| LEADER |
00000cam a2200000Mi 4500 |
| 001 |
SCIDIR_ocn967095798 |
| 003 |
OCoLC |
| 005 |
20231120112202.0 |
| 006 |
m d |
| 007 |
cr ||||||||||| |
| 008 |
161209t20172017ne a ob 001 0 eng d |
| 040 |
|
|
|a IDEBK
|b eng
|e rda
|c IDEBK
|d OPELS
|d OCLCF
|d YDX
|d OCLCO
|d OCLCQ
|d OTZ
|d IDEBK
|d OCLCQ
|d D6H
|d U3W
|d UKMGB
|d WYU
|d OCLCO
|d VT2
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 015 |
|
|
|a GBB702455
|2 bnb
|
| 016 |
7 |
|
|a 018161788
|2 Uk
|
| 019 |
|
|
|a 1066441878
|a 1162264284
|a 1235845097
|
| 020 |
|
|
|a 9780128035535
|q (electronic bk.)
|
| 020 |
|
|
|a 0128035536
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128035474
|
| 020 |
|
|
|z 0128035471
|
| 035 |
|
|
|a (OCoLC)967095798
|z (OCoLC)1066441878
|z (OCoLC)1162264284
|z (OCoLC)1235845097
|
| 050 |
|
4 |
|a RC681
|
| 060 |
|
4 |
|a WG 210
|
| 082 |
0 |
4 |
|a 616.12
|2 23
|
| 100 |
1 |
|
|a Gottlieb, Roberta A.,
|e author.
|
| 245 |
1 |
0 |
|a Cardio-oncology :
|b principles, prevention and management /
|c Roberta A. Gottlieb, Puja K. Mehta.
|
| 264 |
|
1 |
|a Amsterdam, [Netherlands] :
|b Academic Press,
|c 2017.
|
| 264 |
|
4 |
|c �2017
|
| 300 |
|
|
|a 1 online resource (358 pages) :
|b illustrations.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Cover; Title page; Copyright page; Contents; List of Contributors; Acknowledgments; Chapter 1 -- Current Trends in Cancer Therapy; PI3K/AKT pathway; Idelelasib; mTOR pathway; mTOR Inhibitors; Temsirolimus; Everolimus; Mitogen-activated protein kinase (MAPK) pathway; RAF Inhibitors; Vemurafenib; Dabrafenib; Sorafenib; MEK Inhibitors; Trametinib; Combination of MEK and BRAF inhibitors; EGFR pathway; EGFR Tyrosine Kinase Inhibitors; Gefitinib; Erlotinib; Afatinib; EGFR Monoclonal Antibodies; Panitumumab; Cetuximab; Human epidermal growth factor receptor 2; Trastuzumab; Pertuzumab; Lapatinib.
|
| 505 |
8 |
|
|a Ado Trastuzumab EmtansineAnaplastic lymphoma kinase pathway; Crizotinib; Ceritinib; Antiangiogenic agents; VEGF pathway; VEGF Monoclonal Antibodies; Bevacizumab; Ramucirumab; VEGF Tyrosine Kinase Inhibitors; Sunitinib; Sorafenib; Pazopanib; Axitinib; Vandetinib; Cabozantinib; Regorafenib; Immunotherapy; Cancer Vaccines; Sipuleucel-T; Adoptive T Cell Immunotherapy; Immune Checkpoint Blockade; CTLA-4 Inhibition; Ipilimumab; PD1/PDL1/PDL2 Inhibition; Nivolumab; Pembroluzimab; Toxicities of Immune Checkpoint Inhibitions; Monitoring Response in Checkpoint Inhibition; Combination Therapy.
|
| 505 |
8 |
|
|a Future DirectionsCyclin dependent kinases and their pathways; Palbociclib; Poly ADP ribose polymerase inhibition; Olaparib; Conclusions; References; Chapter 2 -- Molecular Mechanisms Underlying Anthracycline Cardiotoxicity: Challenges in Cardio-Oncology; Introduction; Impaired redox signaling; Iron overload in mitochondria; Calcium overload in mitochondria; Altered mitochondrial dynamics in anthracyclines; Respiratory defects and altered metabolism in anthracycline cardiotoxicity; Autophagy in anthracycline cardiotoxicity.
|
| 505 |
8 |
|
|a Deregulated molecular signaling pathways in anthracycline cardiotoxicityGender-specific cardiotoxic effects of anthracycline; Anthracyclines and cardiac remodeling; Strategies to prevent doxorubicin cardiotoxicity; Conclusions; References; Chapter 3 -- Common Pathways in Cancer, Tumor Angiogenesis and Vascular Disease; Introduction; Hedgehog signaling; Notch signaling; Vascular targets for chemotherapy-angiogenesis; Vascular targets for chemotherapy-vasculogenic mimicry; Vascular targets for chemotherapy-microvesicular trafficking; Vascular targets for chemotherapy-vessel maturation.
|
| 505 |
8 |
|
|a Hedgehog and cancer biologyHedgehog inhibitors in cancer therapy; Hedgehog and vascular biology; Notch signaling and tumor biology; Notch inhibitors; Notch signaling and vascular biology; Chemotherapy and vascular disease; Conclusions; References; Chapter 4 -- Molecular Mechanisms of Anthracycline-Induced Cardiotoxicity; Historical and clinical perspectives; Risk factors; Molecular mechanisms of DOX mediated cardiotoxicity; Reactive Oxygen Species Production; Enzymatic Reaction; DOX-Fe Complexes; DOX/DNA/Top-II Beta Ternary Complex; Strategies to limit anthracycline toxicities.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 650 |
|
0 |
|a Heart
|x Cancer.
|
| 650 |
|
2 |
|a Heart Diseases
|x etiology
|0 (DNLM)D006331Q000209
|
| 650 |
|
2 |
|a Heart Neoplasms
|0 (DNLM)D006338
|
| 650 |
|
6 |
|a C�ur
|x Cancer.
|0 (CaQQLa)201-0289198
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Heart
|x Cancer
|2 fast
|0 (OCoLC)fst01767346
|
| 700 |
1 |
|
|a Mehta, Puja K.,
|e author.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128035474
|z Texto completo
|
